menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    ARS Pharmaceuticals Reports Q4 & Full Year 2024 Financial Result

    GLOBENEWSWIRE

    FDA expands use of ARS Pharma`s allergic reaction nasal spray

    REUTERS

    ARS Pharmaceuticals: FDA Approves neffy® 1 mg for Pediatric Anaph

    GLOBENEWSWIRE

    ARS Pharma Schedules Q4, Full-Year 2024 Earnings Call, Events

    GLOBENEWSWIRE

    ARS Pharma’s Neffy Added To OptumRx, Cigna, Navitus Formularies

    GLOBENEWSWIRE

    ARS Pharmaceuticals to Present neffy® Data at 2025 AAAAI Meeting

    GLOBENEWSWIRE

    ARS Pharma to Participate in Oppenheimer 35th Annual Conference

    GLOBENEWSWIRE

    ARS Launches neffyinSchools Program Offering Free Epinephrine

    GLOBENEWSWIRE

    ARS Pharma Reports Q4 Results And 2025 Goals For neffy Nasal Spray

    GLOBENEWSWIRE

    ARS Pharma Files For neffy® Approval In Canada and UK

    GLOBENEWSWIRE

    ARS Pharma Announces Neffy Available on Express Scripts Formularies

    GLOBENEWSWIRE

    ARS Pharma to Participate in 43rd J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    ARS Pharma Files for neffy® Approval in China, Japan & Australia

    GLOBENEWSWIRE

    ARS Pharma Launches neffyinSchools Program for Epinephrine Access

    GLOBENEWSWIRE

    ARS Pharma Reports Q3 2024 Financial Results & Business Updates

    GLOBENEWSWIRE

    ALK licenses rights to neffy for emergency treatment of Anaphylaxis

    GLOBENEWSWIRE

    ARS Pharmaceuticals to Host Q3 2024 Call & Present at Conferences

    GLOBENEWSWIRE

    ARS Pharmaceuticals Showcases Data At ACAAI Annual Meeting

    GLOBENEWSWIRE

    BlinkRx Offers Neffy, The First Needle-Free Epinephrine Treatment

    BUSINESSWIRE

    ARS Pharmaceuticals` Neffy Poised To Disrupt Epinephrine Market

    EXPRESSPHARMA

    Renaissance Lakewood Backs ARS Pharma’s Nasal Spray For Allergies

    PRESS RELEASE

    GoodRx Announces Lowest Cash Price For Neffy

    BUSINESSWIRE

    ARS Pharma Announces US Availability Of Neffy Nasal Spray

    GLOBENEWSWIRE

    ARS Pharmaceuticals To Participate In Cantor Conference

    GLOBENEWSWIRE

    ARS Pharmaceuticals Submits sNDA For neffy 1 mg Dose

    GLOBENEWSWIRE

    ARS Launches Pre-Ordering For Needle-Free neffy®

    GLOBENEWSWIRE

    ARS Pharmaceuticals`s Eurneffy (epinephrine) Receives Approval in Europe

    EMA

    ARS Pharma Launches Epinephrine Nasal Spray With High Potential

    FIERCE PHARMA

    ARS Pharma`s Neffy® Approved As First Needle-Free Anaphylaxis Treatment

    GLOBENEWSWIRE

    ARS Pharmaceuticals To Participate In Wedbush PacGrow Healthcare Conference

    GLOBENEWSWIRE

    ARS Pharmaceuticals Reports Q2 2024 Results And Business Highlights

    GLOBENEWSWIRE

    ARS Pharma`s EURneffy Nasal Spray Recommended by CHMP for Anaphylaxis

    GLOBENEWSWIRE

    ARS Highlights neffy Regulatory Progress, Q1 2024 Financials

    GLOBENEWSWIRE

    ARS Submits neffy® Response To EMA, Partners With CSL Seqirus

    GLOBENEWSWIRE

    ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy®

    GLOBENEWSWIRE

    ARS gears up for neffy US approval

    PHARMACEUTICAL TECHNOLOGY

    ARS Provides Business Update and Reports Q4 and FY3 Financial Results

    GLOBENEWSWIRE

    ARS Pharmaceuticals Reviews Commercial Opportunity at neffy Investor Day

    GLOBENEWSWIRE

    ARS Pharmaceuticals to Participate in the Leerink Partners Biopharma Conference

    GLOBENEWSWIRE

    ARS Pharmaceuticals announces neffy® meets primary endpoints

    GLOBENEWSWIRE

    ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

    GLOBENEWSWIRE

    ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    ARS Pharma Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy

    GLOBENEWSWIRE

    Single and Repeat Dose Clinical Study of neffy Published

    GLOBENEWSWIRE

    FDA Issues CRL for neffy NDA with Request for Additional Study

    GLOBENEWSWIRE

    ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

    GLOBENEWSWIRE

    ARS Pharmaceuticals Highlights Progress and Reports 1Q 2023 FYR Results

    GLOBENEWSWIRE

    FDA adcomm votes in favor of ARS Pharmaceuticals` EpiPen alternative

    ENDPTS

    ARS Pharma Announces Briefing Documents for FDA Advisory Committee on neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals Announces FDA Advisory Committee for neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals Highlights Progress and 4Q & 2022 FYR

    GLOBENEWSWIRE

    ARS Pharmaceuticals Announces Presentation of Data Supporting neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals Reacquires European Marketing Rights to neffy

    GLOBENEWSWIRE

    ARS to Participate in SVB Securities Virtual Global Biopharma Conference 2023

    GLOBENEWSWIRE

    FDA Accepted Intranasal Epinephrine NDA of Ars Pharmaceuticals

    BIONJ

    ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy

    GLOBENEWSWIRE

    ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

    BIOSPACE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.